Loading
FibroGen
A fibrosis-focused biotech whose anti-CTGF antibody pamrevlumab failed phase 3 trials in pancreatic cancer and in lung fibrosis.
Overview
FibroGen, listed on Nasdaq, built its pipeline on connective tissue growth factor biology and on the anaemia drug roxadustat. Pamrevlumab was its oncology bet, tested in locally advanced pancreatic cancer in the LAPIS trial and in a Precision Promise arm; both were negative in 2024, and the programme was discontinued.
Headquarters
San Francisco, California, United States, US
Scorecard
All companies#462of 1245 companies, score 6
- modalities +2
- registry trials +7
- failures -3
0 approved, 0 in phase 3, 0 earlier, 0 targets, 14 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Founded
1993
Products
1NegativeMonoclonal antibody against connective tissue growth factor (CTGF)
Pamrevlumab targeted the scar-like tissue around pancreatic tumours; its phase 3 LAPIS trial in locally advanced disease did not lengthen survival.
Connected
4Similar pages
cancers
drugs
NegativeMonoclonal antibody against connective tissue growth factor (CTGF)
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
fibrogen.com · 1
Wikipedia · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Add Wikidata ids and Wikipedia links for 80 more companies · diff · file
Sourced, not expert-reviewed